Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Investigating CYM as a target for the treatment of MYC-driven group 3 medulloblastoma
FY 2020-21
Summary
Investigating CYM as a target for the treatment of MYC-driven medulloblastoma Medulloblastoma (MB) is the most common malignant brain tumour in children. An increased amount of a protein named MYC in some MB tumours is strongly associated with an increased likelihood of metastasis and poor outcome. Unfortunately, MYC is a difficult protein to target with drugs. However, data from our lab show that targeting and inhibiting another protein named CYM indirectly affects MYC, causing human MB cells to stop growing. Furthermore, we believe CYM is a much more easily druggable target than MYC. There is still a lot we do not know about CYM. This project has two main aims: to determine the localisation of CYM (i.e. where it is in the cell), and to determine whether inhibition of CYM reduces tumour growth and increases survival. If it does, that would indicate that it can be targeted to treat cancer. The localisation of CYM will be investigated by looking for its presence in human MB cells as well as in the cell media. Thin sections from MB tumours will be stained to reveal CYM under the microscope. MB tumour growth and survival will be assessed in mice, comparing animals that have been treated with antibodies against CYM to those which have received an inactive control. Using gene editing CYM will then be deleted from human MB cells and these cells will be used to compare tumour growth and survival to unedited MB tumours. MYC is one of the most frequently upregulated proteins in cancer. Beyond MB, the ability to target MYC through the inhibition of CYM could improve the prognoses of a wide range of deadly cancers including lymphoma, breast cancer, prostate cancer, and melanoma.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
449483
Name
Livingston Bryn
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating CYM as a target for the treatment of MYC-driven group 3 medulloblastoma
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Brain Tumor; Cancer; In Vivo; Medulloblastoma; Molecular Biology; Myc; Neuroscience; Pediatric; Secreted Factors; Targeted Therapy
Abstract
Investigating CYM as a target for the treatment of MYC-driven medulloblastoma Medulloblastoma (MB) is the most common malignant brain tumour in children. An increased amount of a protein named MYC in some MB tumours is strongly associated with an increased likelihood of metastasis and poor outcome. Unfortunately, MYC is a difficult protein to target with drugs. However, data from our lab show that targeting and inhibiting another protein named CYM indirectly affects MYC, causing human MB cells to stop growing. Furthermore, we believe CYM is a much more easily druggable target than MYC. There is still a lot we do not know about CYM. This project has two main aims: to determine the localisation of CYM (i.e. where it is in the cell), and to determine whether inhibition of CYM reduces tumour growth and increases survival. If it does, that would indicate that it can be targeted to treat cancer. The localisation of CYM will be investigated by looking for its presence in human MB cells as well as in the cell media. Thin sections from MB tumours will be stained to reveal CYM under the microscope. MB tumour growth and survival will be assessed in mice, comparing animals that have been treated with antibodies against CYM to those which have received an inactive control. Using gene editing CYM will then be deleted from human MB cells and these cells will be used to compare tumour growth and survival to unedited MB tumours. MYC is one of the most frequently upregulated proteins in cancer. Beyond MB, the ability to target MYC through the inhibition of CYM could improve the prognoses of a wide range of deadly cancers including lymphoma, breast cancer, prostate cancer, and melanoma.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Livingston, Bryn
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~